BRAF inhibition in refractory hairy-cell leukemia
To the Editor: Hairy-cell leukemia (HCL) is a mature B-cell lymphoid cancer that is commonly treated with purine analogues.1 Virtually all patients with HCL carry the BRAF V600E mutation, which constitutively activates the MEK-ERK pathway and which can be inhibited in vitro by the mutation-specific...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
May 24, 2012
|
| In: |
The New England journal of medicine
Year: 2012, Volume: 366, Issue: 21, Pages: 2038-2040 |
| ISSN: | 1533-4406 |
| DOI: | 10.1056/NEJMc1202124 |
| Online Access: | Verlag, Volltext: http://dx.doi.org/10.1056/NEJMc1202124 Verlag, Volltext: https://doi.org/10.1056/NEJMc1202124 
|
| Author Notes: | Sascha Dietrich, Hanno Glimm, Mindaugas Andrulis, Christof von Kalle, Anthony D. Ho, Thorsten Zenz |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1571541683 | ||
| 003 | DE-627 | ||
| 005 | 20230428184859.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180329s2012 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1056/NEJMc1202124 |2 doi | |
| 035 | |a (DE-627)1571541683 | ||
| 035 | |a (DE-576)501541683 | ||
| 035 | |a (DE-599)BSZ501541683 | ||
| 035 | |a (OCoLC)1341000866 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Dietrich, Sascha |d 1979- |e VerfasserIn |0 (DE-588)136406300 |0 (DE-627)694354635 |0 (DE-576)301003408 |4 aut | |
| 245 | 1 | 0 | |a BRAF inhibition in refractory hairy-cell leukemia |c Sascha Dietrich, Hanno Glimm, Mindaugas Andrulis, Christof von Kalle, Anthony D. Ho, Thorsten Zenz |
| 264 | 1 | |c May 24, 2012 | |
| 300 | |a 3 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 29.03.2018 | ||
| 520 | |a To the Editor: Hairy-cell leukemia (HCL) is a mature B-cell lymphoid cancer that is commonly treated with purine analogues.1 Virtually all patients with HCL carry the BRAF V600E mutation, which constitutively activates the MEK-ERK pathway and which can be inhibited in vitro by the mutation-specific BRAF inhibitor PLX-4720.2 BRAF mutations have been identified in melanoma but are found across cancers.3 An inhibitor of mutated BRAF (vemurafenib) has transformed the treatment of melanoma. It is unclear whether this clinical efficacy can be extrapolated to other cancers.4,5 We used vemurafenib in a patient with refractory HCL and a pressing need for . . . | ||
| 700 | 1 | |a Glimm, Hanno |d 1967- |e VerfasserIn |0 (DE-588)113880677 |0 (DE-627)51985120X |0 (DE-576)289777879 |4 aut | |
| 700 | 1 | |a Andrulis, Mindaugas |d 1972- |e VerfasserIn |0 (DE-588)131682172 |0 (DE-627)512716587 |0 (DE-576)298670534 |4 aut | |
| 700 | 1 | |a Kalle, Christof von |d 1962- |e VerfasserIn |0 (DE-588)1036481115 |0 (DE-627)75107926X |0 (DE-576)168957396 |4 aut | |
| 700 | 1 | |a Ho, Anthony Dick |d 1948- |e VerfasserIn |0 (DE-588)108692477 |0 (DE-627)504904205 |0 (DE-576)19010466X |4 aut | |
| 700 | 1 | |a Zenz, Thorsten |d 1970- |e VerfasserIn |0 (DE-588)114963738 |0 (DE-627)577184202 |0 (DE-576)180278266 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The New England journal of medicine |d Waltham, Mass. : MMS, 1928 |g 366(2012), 21, Seite 2038-2040 |h Online-Ressource |w (DE-627)266889484 |w (DE-600)1468837-2 |w (DE-576)075962454 |x 1533-4406 |7 nnas |a BRAF inhibition in refractory hairy-cell leukemia |
| 773 | 1 | 8 | |g volume:366 |g year:2012 |g number:21 |g pages:2038-2040 |g extent:3 |a BRAF inhibition in refractory hairy-cell leukemia |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |a Dietrich, Sascha, 1979 - |t BRAF inhibition in refractory hairy-cell leukemia |d 2012 |w (DE-627)1571544666 |w (DE-576)501544666 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1056/NEJMc1202124 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u https://doi.org/10.1056/NEJMc1202124 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180329 | ||
| 993 | |a Article | ||
| 994 | |a 2012 | ||
| 998 | |g 114963738 |a Zenz, Thorsten |m 114963738:Zenz, Thorsten |d 910000 |d 950000 |d 950950 |e 910000PZ114963738 |e 950000PZ114963738 |e 950950PZ114963738 |k 0/910000/ |k 1/910000/950000/ |k 2/910000/950000/950950/ |p 6 |y j | ||
| 998 | |g 108692477 |a Ho, Anthony Dick |m 108692477:Ho, Anthony Dick |d 910000 |d 910100 |e 910000PH108692477 |e 910100PH108692477 |k 0/910000/ |k 1/910000/910100/ |p 5 | ||
| 998 | |g 1036481115 |a Kalle, Christof von |m 1036481115:Kalle, Christof von |d 140000 |e 140000PK1036481115 |k 0/140000/ |p 4 | ||
| 998 | |g 131682172 |a Andrulis, Mindaugas |m 131682172:Andrulis, Mindaugas |d 910000 |d 912000 |e 910000PA131682172 |e 912000PA131682172 |k 0/910000/ |k 1/910000/912000/ |p 3 | ||
| 998 | |g 113880677 |a Glimm, Hanno |m 113880677:Glimm, Hanno |d 140000 |e 140000PG113880677 |k 0/140000/ |p 2 | ||
| 998 | |g 136406300 |a Dietrich, Sascha |m 136406300:Dietrich, Sascha |d 910000 |d 910100 |e 910000PD136406300 |e 910100PD136406300 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1571541683 |e 3004493691 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"person":[{"role":"aut","display":"Dietrich, Sascha","given":"Sascha","family":"Dietrich"},{"display":"Glimm, Hanno","given":"Hanno","family":"Glimm","role":"aut"},{"given":"Mindaugas","family":"Andrulis","display":"Andrulis, Mindaugas","role":"aut"},{"display":"Kalle, Christof von","given":"Christof von","family":"Kalle","role":"aut"},{"family":"Ho","given":"Anthony Dick","display":"Ho, Anthony Dick","role":"aut"},{"role":"aut","display":"Zenz, Thorsten","given":"Thorsten","family":"Zenz"}],"note":["Gesehen am 29.03.2018"],"physDesc":[{"extent":"3 S."}],"origin":[{"dateIssuedKey":"2012","dateIssuedDisp":"May 24, 2012"}],"title":[{"title":"BRAF inhibition in refractory hairy-cell leukemia","title_sort":"BRAF inhibition in refractory hairy-cell leukemia"}],"id":{"eki":["1571541683"],"doi":["10.1056/NEJMc1202124"]},"relHost":[{"origin":[{"publisher":"MMS ; MMS","publisherPlace":"Waltham, Mass. ; Boston, Mass.","dateIssuedDisp":"1928-","dateIssuedKey":"1928"}],"id":{"issn":["1533-4406"],"zdb":["1468837-2"],"eki":["266889484"]},"note":["Gesehen am 04.08.25"],"physDesc":[{"extent":"Online-Ressource"}],"disp":"BRAF inhibition in refractory hairy-cell leukemiaThe New England journal of medicine","recId":"266889484","corporate":[{"role":"isb","display":"Massachusetts Medical Society"}],"part":{"year":"2012","volume":"366","issue":"21","text":"366(2012), 21, Seite 2038-2040","pages":"2038-2040","extent":"3"},"type":{"media":"Online-Ressource","bibl":"periodical"},"titleAlt":[{"title":"NEJM"}],"title":[{"subtitle":"NEJM","title_sort":"New England journal of medicine","title":"The New England journal of medicine"}],"language":["eng"],"name":{"displayForm":["Massachusetts Medical Society"]},"pubHistory":["198.1928 -"]}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"name":{"displayForm":["Sascha Dietrich, Hanno Glimm, Mindaugas Andrulis, Christof von Kalle, Anthony D. Ho, Thorsten Zenz"]},"recId":"1571541683"} | ||
| SRT | |a DIETRICHSABRAFINHIBI2420 | ||